Suppr超能文献

脊髓和外周机制分别导致瑞芬太尼诱发痛觉过敏的发生。

Spinal and Peripheral Mechanisms Individually Lead to the Development of Remifentanil-induced Hyperalgesia.

作者信息

Horii Yasuhiko, Matsuda Megumi, Takemura Hitomi, Ishikawa Daiki, Sawa Teiji, Amaya Fumimasa

机构信息

Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kyoto, Japan; Research Unit for the Neurobiology of Pain, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

出版信息

Neuroscience. 2020 Oct 15;446:28-42. doi: 10.1016/j.neuroscience.2020.08.014. Epub 2020 Aug 18.

Abstract

The present study was performed to determine neuronal loci and individual molecular mechanisms responsible for remifentanil-induced hyperalgesia. The effect of methylnaltrexone (MNX) on remifentanil-induced behavioral hyperalgesia was assessed to distinguish contributions of the peripheral and/or central nervous system to remifentanil-induced hyperalgesia. Phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) in the dorsal root ganglion (DRG) neurons after remifentanil infusion, and the effect of a p38MAPK inhibitor on remifentanil-induced hyperalgesia were analyzed to investigate involvement of p38MAPK in the peripheral mechanisms of remifentanil-induced hyperalgesia. Spinal levels of prodynorphin mRNA after remifentanil infusion, and the effect of the BK2 bradykinin receptor antagonist on remifentanil-induced hyperalgesia were investigated to assess potential spinal mechanisms. The effects of MNX and BK2 antagonists on remifentanil-induced exacerbation of post-incisional hyperalgesia were also investigated using behavioral analysis. Remifentanil infusion induced hyperalgesia in the early (4 h to 2 days) and late (8-14 days) post-infusion periods. MNX inhibited hyperalgesia only during the early post-infusion period. p38MAPK phosphorylation was observed in the DRG neuron, and the p38MAPK inhibitor inhibited hyperalgesia during the early post-infusion period. Prodynorphin expression increased in the spinal cord, and a BK2 antagonist inhibited hyperalgesia during the late post-infusion period. Remifentanil-induced exacerbation of incisional hyperalgesia was inhibited by MNX and the BK2 antagonist. The present study demonstrated that remifentanil activates peripheral and spinal neurons to promote chronologically distinctive hyperalgesia. p38MAPK phosphorylation in the DRG neuron leads to peripherally-driven hyperalgesia during the early post-infusion period, while spinal dynorphin-bradykinin signaling promotes hyperalgesia during the late post-infusion period.

摘要

本研究旨在确定导致瑞芬太尼诱发痛觉过敏的神经元位点及个体分子机制。评估甲基纳曲酮(MNX)对瑞芬太尼诱发的行为性痛觉过敏的影响,以区分外周和/或中枢神经系统对瑞芬太尼诱发痛觉过敏的作用。分析瑞芬太尼输注后背根神经节(DRG)神经元中p38丝裂原活化蛋白激酶(p38MAPK)的磷酸化情况,以及p38MAPK抑制剂对瑞芬太尼诱发痛觉过敏的影响,以研究p38MAPK在瑞芬太尼诱发痛觉过敏外周机制中的作用。研究瑞芬太尼输注后脊髓中前强啡肽原mRNA水平,以及BK2缓激肽受体拮抗剂对瑞芬太尼诱发痛觉过敏的影响,以评估潜在的脊髓机制。还通过行为分析研究了MNX和BK2拮抗剂对瑞芬太尼诱发的切口后痛觉过敏加重的影响。瑞芬太尼输注在输注后早期(4小时至2天)和晚期(8 - 14天)诱发痛觉过敏。MNX仅在输注后早期抑制痛觉过敏。在DRG神经元中观察到p38MAPK磷酸化,p38MAPK抑制剂在输注后早期抑制痛觉过敏。脊髓中前强啡肽原表达增加,BK2拮抗剂在输注后晚期抑制痛觉过敏。MNX和BK2拮抗剂抑制了瑞芬太尼诱发的切口痛觉过敏加重。本研究表明,瑞芬太尼激活外周和脊髓神经元,以促进按时间顺序具有明显差异的痛觉过敏。DRG神经元中的p38MAPK磷酸化在输注后早期导致外周驱动的痛觉过敏,而脊髓强啡肽 - 缓激肽信号传导在输注后晚期促进痛觉过敏。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验